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HB-EGF is produced in the peritoneal cavity and enhances tonitis also induces an acute inflammatory reaction in
mesothelial cell adhesion and migration. the peritoneal membrane and is associated with shedding
Background. The mesothelial cell monolayer lining the peri- of mesothelial cells. The peritoneal dialysate is a high-toneal membrane needs constant repair in response to peritoni-
glucose, hypertonic, lactate-buffered, acidic solution thattis and to the toxicity of peritoneal dialysate. In many continu-
is toxic to mesothelial cells in vitro and has been impli-ous ambulatory peritoneal dialysis (CAPD) patients, the repair
process progressively fails, and membrane dysfunction and fi- cated in long-term damage of the peritoneal membrane
brosis occur. Heparin-binding epidermal growth factor-like [1–3]. Shedding of peritoneal mesothelial cells occurs
growth factor (HB-EGF) has an important role in wound repair continuously during peritoneal dialysis and is particu-and is also fibrogenic, and thus may be involved in these pro-
larly marked soon after CAPD is initiated [4, 5]. Thecesses in the peritoneal cavity.
wounding induced by these processes will stimulate re-Methods. The presence of HB-EGF, its receptors, and its
associated proteins was determined in peritoneal membrane bi- pair responses within the peritoneal membrane, includ-
opsies, cultured human peritoneal mesothelial cells (HPMCs), ing an attempt by the mesothelial cells to repopulate
and peritoneal macrophages from CAPD patients by reverse denuded areas. Histologic studies of the peritoneal mem-transcription-polymerase chain reaction, flow cytometry, and
brane from patients on long-term CAPD show loss ofimmunofluorescence immunocytochemistry with confocal mi-
mesothelial cells and replacement of the membrane bycroscopy. HB-EGF effects on HPMC adhesion were measured
by a static adhesion assay, on integrin expression by flow cytom- collagen-based fibrous tissue [6, 7], suggesting that the
etry, and on migration by wound healing and chemotaxis assays. response to recurrent damage during peritoneal dialysis
Results. HB-EGF, its receptors HER-1 and HER-4, and the is inadequate or becomes exhausted. In some patients,associated proteins CD9, CD44, and integrin a3b1 were expressed the fibrotic reaction is progressive and potentially lifeby HPMCs and peritoneal macrophages. HB-EGF colocalized
threatening and leads to dialysis failure.with HER-1 and HER-4 in HPMCs and induced their adhesion
to collagen type I, expression of b1 integrins, and migration. It is likely that the wound repair response of peritoneal
Conclusions. HB-EGF is produced by cells in the peritoneal mesothelial cells is analogous to that of epithelial cell
cavity of CAPD patients and has functional effects on HPMCs layers elsewhere in the body (for example, skin), wherethat would facilitate repair of the mesothelial layer.
cells at the edge of the wound proliferate and migrate
in to cover the defect [8, 9]. The migration occurs over
extracellular matrix (ECM) molecules (such as vitronec-
The peritoneal membrane and the mesothelial cells
tin, fibronectin, collagen, laminin) that are exposed or
that line it are the key structures permitting the feasibility
deposited at the site of wounding. Growth factors, such
of continuous ambulatory peritoneal dialysis (CAPD).
as platelet-derived growth factors (PDGFs), fibroblastUnfortunately, the dialysis process itself exposes them
growth factors (FGFs), transforming growth factor-bto repeated insults, which ultimately in many patients
(TGF-b), and members of the epidermal growth factorlead to loss of dialysis and ultrafiltration functions. Peri-
(EGF) family [for example, EGF, TGF-a, and heparin-
binding EGF-like growth factor (HB-EGF)] regulate this
complex process. They are released by cells infiltratingKey words: wound repair, CAPD, peritonitis, toxic dialysate, fibro-
genesis, inflammation, ultrafiltration. the wounded area (for example, macrophages, platelets)
or by the epithelial cells themselves [8].Received for publication July 22, 1999
There is limited information about the production orand in revised form September 1, 2000
Accepted for publication September 6, 2000 function of growth factors in the peritoneal cavity of
CAPD patients. Peritoneal macrophages are potentiallyÓ 2001 by the International Society of Nephrology
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a rich source of growth factors, and these cells are chroni- pressed with it, and that exogenous HB-EGF stimulates
functional responses in the mesothelial cells that maycally activated during peritoneal dialysis [10, 11]. Mito-
genic activity was demonstrated in peritoneal dialysis facilitate their response to wounding.
effluent by Molina et al [12], but they did not further
characterize the growth factors in the fluid. TGF-b has
METHODS
received considerable attention as a fibrogenic cytokine
Isolation and culture of human peritoneal[13, 14], and most studies of growth factors in the perito-
mesothelial cellsneal cavity have concentrated on it and its potential role
in peritoneal repair and fibrosis [15]. Peritoneal macro- Human peritoneal mesothelial cells (HPMCs) were
isolated from discarded peritoneal dialysate and culturedphages from CAPD patients produce TGF-b1 [16, 17],
and cultured peritoneal mesothelial cells constitutively according to our published method [4]. Patients with cur-
rent or recent peritonitis were not used as a source ofsynthesize TGF-b1 and -b2, but not -b3 [18, 19]. Interleu-
kin-1 (IL-1) treatment of peritoneal mesothelial cells cells. No patients were being treated with corticosteroids
or other immunosuppressants that might affect cytokinefurther increases production of TGF-b1 and TGF-b2
[18, 20], as does exposure of the cells to high glucose expression. Spent dialysis fluid was collected. Cellular
components were isolated using low-speed (200 3 g)concentrations as well as spent peritoneal dialysate
[19, 21]. Yang et al also showed that IL-1 increased centrifugation, washed with Hanks balanced salt solution
(HBSS), and suspended in BIORICH 1 medium (ICNproduction of collagen type 1 and fibronectin by the
cultured mesothelial cells, but that the increase in fibro- Flow, Irvine, Scotland) supplemented with 10 mmol/L
HEPES (ICN Biomedicals, Aurora, OH, USA), 50 nmol/Lnectin production was only partially inhibited by a neu-
tralizing anti–TGF-b antibody [20]. Lin et al found in- hydrocortisone (Pharmacia & Upjohn, North Ryde, New
South Wales, Australia), 4 mmol/L glutamine, 15 mmol/Lcreased levels of TGF-b1 in peritoneal dialysate and
peritoneal leukocytes at times of peritonitis and showed glucose (Life Technologies, Grand Island, NY, USA),
0.04 U/mL penicillin, 0.4 U/mL gentamycin (CSL, Park-persistent TGF-b1 mRNA expression in the peritoneal
membrane of one patient following multiple episodes of ville, Victoria, Australia), 30 mg/mL cysteine (ICN Bio-
medicals), and 5% fetal calf serum (FCS; CSL). EGFperitonitis [17]. They tentatively proposed that persistent
TGF-b1 expression would predict peritoneal fibrosis fol- (Life Technologies), 10 ng/mL, was added to the cultures
for the first 24 hours to aid initial establishment, but waslowing peritonitis. TGF-b1 is chemotactic and mitogenic
for fibroblasts and induces production of ECM molecules omitted in all subsequent culturing. The concentration
of glucose was kept standard and unchanged in all experi-[13, 14, 22], but there is disagreement in the literature
as to whether it is mitogenic for peritoneal mesothelial ments and was derived during our previous work estab-
lishing optimal conditions for the ex vivo growth andcells. In an early article, Dobbie claimed that TGF-b
increased mesothelial cell proliferation [23], but more proliferation of the cells. Preliminary experiments also
showed that HPMCs cultured in glucose concentrationsrecent publications showed an inhibition of proliferation
[15, 24]. The net effect of increased fibroblast chemo- ranging from 5 to 240 mmol/L uniformly expressed
mRNA for HB-EGF (data not shown). Cells were placedtaxis, proliferation, and matrix production combined
with inhibition of mesothelial proliferation would be im- into 25 cm2 tissue culture flasks (Becton Dickinson,
Franklin Lakes, NJ, USA) precoated with 1 mg/mL typepaired mesothelial wound repair and increased fibrosis.
TGF-b also promotes mesothelial cell synthesis and se- I collagen (Collaborative Biomedical, Bedford, MA,
USA) and incubated overnight at 378C, 5% CO2. Nonad-cretion of plasminogen activator inhibitor-1, which may
impair fibrin degradation further as well as the removal herent material was removed the next day with two brief
washes with HBSS, and the adherent population wasof poorly organized matrix components [25, 26].
The growth factor EGF is mitogenic for peritoneal incubated at 378C, 5% CO2 in fresh medium. The cells
proliferate to form a monolayer with features typical ofmesothelial cells and induces a morphological change
toward a fibroblastic phenotype [4, 27]. It also enhances cultured HPMCs and are uniformly positive for cytokera-
tins 8 and 18 and negative for macrophage and othertheir migratory capacity and adhesion to ECM molecules
[4], and thus is a potential candidate for regulating wound leukocyte markers [4]. HB-EGF (R&D Systems, Minne-
apolis, MN, USA) was added where indicated.responses by the peritoneal membrane. The production
and function of EGF family members in the peritoneal
Isolation of peritoneal macrophagescavity of CAPD patients have not previously been inves-
tigated. In this article, we show that a member of this Peritoneal macrophages were isolated from discarded
peritoneal dialysis effluent according to the method offamily (HB-EGF) is synthesized in the peritoneal cavity
by resident macrophages and mesothelial cells, that peri- Hart, Cooper and Finlay-Jones [28]. In brief, the cells
from the fluid were isolated as described previously intoneal mesothelial cells express both the receptors for
HB-EGF and the cell surface molecules usually coex- this article, washed with HBSS and suspended in 15
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mL HBSS. Lymphoprep (Nycomed Pharma AS, Oslo, EA Wayner, Seattle, WA, USA), P1B5 (CD49c; Dako
Corp.), 1AA2 (CD9; L. Ashman, Hanson Center forNorway) was carefully layered beneath the cell suspen-
sion and centrifuged at 800 3 g for 20 minutes. The Cancer Research, Adelaide, Australia), JG7.C9 (CD44;
Leavesley), and DE10 (anti-HB-EGF; Power). The DE10buoyant cellular material was recovered from the Lypho-
prep–aqueous interface, resuspended in HBSS, and sub- antibody specifically recognizes the mature, cleaved form
of HB-EGF, binds only to purified HB-EGF (and notjected to another cycle of density isolation. Cells recov-
ered were suspended to 106 cells per milliliter in RPMI other EGF family members) in an enzyme-linked immu-
nosorbent assay, binds to human HB-EGF–transfected1640 medium (Life Technologies), supplemented with
0.04 U/mL penicillin, 0.4 U/mL gentamycin, 30 mg/mL NIH-3T3 cells, and blocks their HB-EGF–mediated
proliferation [29].cysteine, and 1% FCS, and placed in 9.6 cm2 dishes
(Corning-Costar, Cambridge, MA, USA). After over-
RNA isolation and PCR analysisnight incubation, adherent cellular material was recov-
ered and processed for analysis by flow cytometry or Cells isolated from spent peritoneal dialysate, perito-
neal biopsies, and cultured HPMCs (,2nd passage) werereverse transcription-polymerase chain reaction (RT-
PCR; discussed later in this article). Macrophages were extracted with the addition of 0.5 mL RNAzol B (Tel-
Test Inc.), and total RNA was prepared according to theidentified as those cells positive for CD14, but negative
for cytokeratins 8 and 18 (epithelial cell specific), factor manufacturer’s instructions. First strand complementary
DNA (cDNA) was synthesized from total RNA fromVIII or von Willebrand factor (endothelial cell specific),
and CD66b (granulocyte specific). each sample, using a cDNA synthesis kit, as per manufac-
turer’s instructions (Cat. No. A3500; Promega Corp.,
Peritoneal membrane biopsy samples Madison, WI, USA). Resultant cDNA product was then
amplified by PCR in a thermal cycler (Corbett Research,Biopsies of peritoneal membrane were taken at the
time of laparoscopic insertion of Tenckhoff catheters in Melbourne, Victoria, Australia) to generate products
corresponding to mRNA encoding gene products listedpatients soon to commence peritoneal dialysis. A biopsy
of approximately 3 mm3 was carefully excised from the later in this article. Amplification cycles were 21 for the
housekeeping gene glyceraldehyde 3-phosphate dehy-peritoneal membrane at a site adjacent to the laparo-
scope entry and placed immediately into ice-cold Mi- drogenase (GAPDH) and 35 for HB-EGF and other
cytokines and receptors. Human-specific mRNA-oligo-chel’s transport medium. Subsequently, each sample was
divided into 1 mm3 into (1) formal saline, (2) OCT em- nucleotide primers (Life Technologies) were designed
with the assistance of Amplify software [30] on the basisbedding medium (Miles Inc., Elkhart, IN, USA) and
snap frozen, or (3) digested in RNAzol B (Tel-Test Inc., of published sequences. This program specifically avoids
the design of primers that may form primer dimers. InFriendswood, TX, USA) and cellular RNA prepared for
PCR analysis (discussed later in this article). all cases, where possible, the priming oligonucleotides
were mRNA specific in that the recognition sites of the
Immunofluorocytometric analysis upstream and downstream primers resided in separate
exons within the genomic sequence. Details of the primerHuman peritoneal mesothelial cells or cultured perito-
neal macrophages were harvested using 0.1 mmol/L eth- pairs are shown in Table 1. Amplification products were
resolved by electrophoresis on a 2% wt/vol agarose gel,ylenediaminetetraacetic acid (EDTA), and transferred
into ice-cold 10% rabbit serum in phosphate-buffered poststained with SYBRGold (Molecular Probes), and
cDNA products fluorescence intensities quantitated withsaline (PBS) for 15 minutes prior to incubation with
unlabeled or FITC-conjugated monoclonal antibodies. ImageQuant software (Molecular Dynamics, Sunnyvale,
CA, USA). Unincorporated oligonucleotides detectedAfter 45 minutes of incubation on ice, unbound antibody
was removed with two washes with cold PBS. Unlabeled by this sensitive system appear at the bottom of the lanes.
To eliminate the synthesis of false-positive products,antibody-treated cells were further incubated with goat
anti-mouse IgG-FITC (Silenus, Hawthorn, Victoria, Aus- PCR reactions were carried out using non–reverse-tran-
scribed RNA and on reaction mixtures in which thetralia) for 45 minutes on ice and unbound antibody re-
moved with cold PBS as previously. Labeled cells were target RNA was omitted.
fixed in 0.3% paraformaldehyde and 2% glucose in PBS,
Fluorescence immunocytochemistryand 10,000 events per sample were analyzed using a
Coulter EPICS XL flow cytometer (Beckman-Coulter Human peritoneal mesothelial cells were grown to
70% confluency on glass cover slips coated with collagenCorp., Hialeah, FL, USA). Monoclonal antibodies used
were LP34 (pan anticytokeratin; Dako Corp., Carpinteria, type I (Collaborative Biomedical), washed in PBS, and
fixed in 4% paraformaldehyde in PBS for 20 minutes.CA, USA), LeuM3 (CD14; Beckman-Coulter Corp.),
80H3 (CD66b; Beckman-Coulter Corp.), U7.27 (isotype The excess paraformaldehyde was neutralized by treat-
ment with 150 mmol/L glycine for 20 minutes and washedcontrol; Beckman-Coulter Corp.), P5D2 (pan b1 integrins;
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Table 1. Details of primers used for PCR analysis
Primer Forward sequence Reverse sequence Accession # Product size
GAPDH 59 cactgacacgttggcagtgg 39 59 catggagaaggctggggctc 39 X01677 417 bp
[nucleotide # 372–391] [nucleotide # 767–786]
HB-EGF 59 tccccagccgattccttgag 39 59 ggagaatgcaaatatgtgaagg 39 M60278 307 bp
[nucleotide # 616–637] [nucleotide # 901–920]
EGF 59 ctgtctgaaccaggactgat 39 59 cttcactcaggtctcagctat 39 X04571 470 bp
[nucleotide # 3266–3285] [nucleotide # 3713–3733]
TGF-a 59 cagcagttggtgtctgagtc 39 59 ccatctaataaataagacatc 39 X70340 339 bp
[nucleotide # 800–819] [nucleotide # 1116–1136]
HER-1 59 gcaaataaaaccggactgaag 39 59 gtggcaccaaagctgtatttg 39 U48722 493 bp
[nucleotide # 623–642] [nucleotide # 1093–1113]
HER-2 59 ctgaggattgtcagagcctga 39 59 gccattgtgcagaattcgtcc 39 X03363 692 bp
[nucleotide # 800–820] [nucleotide # 1471–1491]
HER-3 59 gcatttaatggcagctagtgc 39 59 aaagcacacaaaataaggaaaacc 39 M34309 219 bp
[nucleotide # 4155–4175] [nucleotide # 4348–4371]
HER-4 59 cagggttgtcaaacgctttc 39 59 ggaggttttgctgctgaac 39 L07868 519 bp
[nucleotide # 3238–3256] [nucleotide # 3735–3754]
with PBS. The fixed cell monolayers were permeabilized and incubated for one hour at 378C. Endogenous cellular
acid phosphatase activity was determined from absor-with 0.3% Triton X-100 in PBS for 20 minutes, washed
bency at 410 nm after pH adjustment with 1 mol/Ltwice with PBS, and blocked with 3% bovine serum
NaOH. Data are expressed as mean of triplicate wells 6albumin (BSA) in PBS for 20 minutes. Cells were then
SD. Statistical significance was determined using Stu-incubated for one hour with either anti–HER-1 mouse
dent’s t-test.monoclonal antibody 528 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or anti-HER-4 rabbit polyclonal
Migration assaysantibody C-18 (Santa Cruz Biotechnology) in PBS/3%
Wound healing. Confluent monolayers of HPMCsBSA. After three washes with PBS, the anti-HER-1–
grown on collagen type I for four days, with or with-and anti-HER-4–treated cells were further incubated for
out the addition of HB-EGF (10 ng/mL) were woundedone hour with Texas Red-X–conjugated goat anti-mouse
(4 mm scrape) using a Teflon policeman, as previously(Molecular Probes) or Texas Red-X–conjugated goat
described [4]. Displaced cells were removed with threeanti-rabbit (Molecular Probes) antibodies, respectively.
washes with HBSS, and fresh culture medium was added.The cover slips were washed three times with PBS and
The position of the wound edge was noted against aincubated for one hour with fluorescein-conjugated
reference grid and measured at 15 individual pointsDE10. Following washing, the cells were counterstained
(5 points each in 3 independent wounds) periodicallywith the nucleic acid specific dye Toto-3 (Molecular
using an ocular graticule. Cultures were refed daily withProbes) and mounted with fluorescent mounting me-
fresh medium containing FCS. Data are expressed asdium (Dako). Images were collected and generated on
mean distance of leading cell(s) from wound origin 6 SD.a confocal laser scanning microscope (Bio-Rad MRC
Chemotaxis. HPMCs (,3rd passage) grown on colla-1024; Bio-Rad Microscopy Division, Hemel Hempstead
gen type I for four days, with or without HB-EGF (10
Herts, UK).
ng/mL), were trypsinized and resuspended to 3 3 105
cells/mL in serum-free medium and placed into the upperStatic adhesion assay
chamber of 12 mm pore size Transwell chambers (Corn-
Cell adhesion was assayed using a standard attach- ing-Costar, Cambridge, MA, USA). Migration after four
ment protocol to purified collagen type I (5 mg/mL in hours in 5% CO2/95% air at 378C toward purified colla-PBS; Collaborative Biomedical) immobilized on Maxi- gen type I (50 mg/mL) or BSA in the lower chamber
sorb plastic microtiter wells (Nunc, Roskilde, Denmark) was determined as acetic acid extractable crystal violet
[31]. HPMCs were grown in standard culture medium staining of the lower membrane surface, as previously
for four days, with or without the addition of HB-EGF described [4]. Data are expressed as mean 6 SD. Statisti-
(10 ng/mL), and were harvested using 0.1 mmol/L EDTA. cal significance was determined using Student’s t-test.
Fifty thousand (5 3 104) cells were added per well and
allowed to attach for 30 minutes. For antibody inhibition
RESULTSexperiments, 20 mg/mL of the anti-b1 integrin mono-
HB-EGF is produced in the peritoneal cavity ofclonal antibody P5D2 were also included. After remov-
CAPD patientsing nonadherent cells using a standardized, low shear wash,
P-nitrophenylphosphate, in 50 mmol/L sodium acetate Reverse transcription-PCR was used to initially screen
cells from the peritoneal cavity of CAPD patients forbuffer, pH 5.0, containing 1% Triton X-100, was added
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In order to identify more specifically the cells expressing
HB-EGF, we utilized the anti-HB-EGF DE10 mono-
clonal antibody (Methods section) for flow cytometric
analysis of peritoneal leukocytes and cultured HPMC
to determine the cell surface expression of HB-EGF
protein. DE10 bound to leukocytes isolated from spent
dialysate, and further analysis showed that the predomi-
nant DE10-positive cells were CD14-positive, CD66b-
negative, a phenotype consistent with macrophages (Fig.
2A). Cultured HPMCs, confirmed as cytokeratin positive
with the LP34 monoclonal antibody, were also recog-
nized by DE10 (Fig. 2B). This pattern was consistent in
the four different patient samples studied, apart from
minor variability in the level of expression.
Receptors for HB-EGF are expressed by HPMCs
from CAPD patients
The initial experiments confirmed that HB-EGF (but
not EGF or TGF-a) is produced in the peritoneal cavity
by peritoneal macrophages and mesothelial cells. We
next sought to determine whether the peritoneal meso-
thelial cells were likely to be responsive to HB-EGF.
The initial approach was to seek evidence for expression
of the appropriate receptors for HB-EGF [human EGF
Fig. 1. Heparin-binding epidermal growth factor-like (HB-EGF), but
receptor (HER)-1 and HER-4] in peritoneal biopsiesneither EGF nor transforming growth factor-a (TGF-a), is expressed
in peritoneal membrane biopsies, freshly isolated peritoneal leukocytes, and on cultured HPMCs. RT-PCR analysis, using appro-
and cultured human peritoneal mesothelial cells (HPMCs) from contin- priate primer pairs, detected mRNA for all four mem-
uous ambulatory peritoneal dialysis (CAPD) patients. Biopsies and
bers of the EGF receptor family (HER-1, -2, -3, and -4)cells were obtained and processed and isolated or cultured according
to the Methods section. mRNA for HB-EGF was detected by RT-PCR in both cases (Fig. 3). mRNA for each receptor was
as described in the Methods section. The lanes and expected product also detectable in samples of peritoneal leukocytes from
sizes are as follows: lane 1, GAPDH (417 bp); lane 2, EGF (470 bp);
CAPD patients (data not shown).lane 3, HB-EGF (307 bp); and lane 4, TGF-a (339 bp). The experiment
was conducted simultaneously using material from four separate pa-
tients. The relevant lanes of samples from one patient were excised Molecules associated with HB-EGF are expressed
and shown for brevity and clarity. by HPMC
Certain transmembrane molecules on the cell surface
(integrin a3b1, CD9, and CD44) are known to be associ-
ated with HB-EGF (Discussion section). We used flowevidence of expression of the following members of the
EGF family: EGF, TGF-a, and HB-EGF. Primer pairs cytometric analysis with specific monoclonal antibodies
to determine whether they are expressed by culturedspecific for each molecule were used to probe RNA
derived from peritoneal leukocytes, biopsies of the peri- HPMCs. The coexpressed molecules CD9, CD49c, and
CD44 were consistently detected on the HPMCs, withtoneal membrane, and cultured HPMCs. mRNA encod-
ing HB-EGF was detectable in each of the sites examined particularly high expression of CD44 being a feature
(Fig. 4).(Fig. 1), but message for EGF and TGF-a was not de-
tected. mRNA for TGF-b was also detectable at each
HB-EGF and its receptors colocalize in HPMCsite (data not shown). This pattern of mRNA expression
was consistent in multiple samples from different pa- Having found evidence that both HB-EGF and its
receptors are expressed by HPMCs, we next sought totients, although it was not possible to comment about
interpatient and intrapatient variability as the RT-PCR determine whether they colocalized in order to further
support our hypothesis that the HB-EGF expression ismethod used was not quantitative.
The sensitivity of the RT-PCR also means that it is functionally significant. Figure 5 shows HPMCs, cultured
on collagen type I-coated cover slips, stained with anti-possible that the HB-EGF message detected in the leu-
kocyte samples and the peritoneal biopsies could be from bodies against HB-EGF (green; Fig. 5 A, D), HER-1
(red; Fig. 5B), and HER-4 (red; Fig. 5E). The permeabil-HPMCs, leukocytes/macrophages, or both. Our previous
work (Methods section) made us confident that the ized cells expressed abundant amounts of each protein,
particularly in a perinuclear distribution with lesserHPMC cultures were not contaminated by leukocytes.
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Fig. 2. Mature HB-EGF protein, detected by
the monoclonal antibody DE10, is detected
on the surface of (A) CD14-positive, CD66b-
negative peritoneal macrophages, and (B)
LP34 (cytokeratin)-positive cultured HPMCs.
Flow cytometric analysis of the binding of
FITC-labeled monoclonal antibodies to the
cells was performed as described in the Meth-
ods section. Background staining (negative)
was detected using a FITC-labeled irrelevant
monoclonal antibody. An illustrative result is
taken from experiments performed on cells
isolated from four different patients.
amounts on the cell surface. The high degree of colocali- proliferation (measured by both cell counting and
3H-thymidine incorporation; data not shown).zation between HB-EGF and its receptors is shown by
Experiments were then performed to assess the effectthe yellow, cumulative emission in Figure 5 C and F.
of HB-EGF on HPMC adhesion to collagen type I. ECM
molecules such as collagen type I are exposed at sitesEffects of exogenous HB-EGF on cultured HPMCs
of wounding, and the wounded cells (such as HPMCs)We next performed a series of experiments to char-
interact with such molecules during the healing phase.acterize the response of HPMCs to exogenously applied
A potential biological consequence of HB-EGF inter-
HB-EGF. Previous work by ourselves and others (dis- actions with its receptor(s) would be to increase the
cussed previously in this article) showed that exoge- adhesive capacity of the mesothelial cells for such ECM
nously applied EGF was mitogenic for HPMCs and molecules. Exogenous HB-EGF (10 ng/mL) induced a
induced a morphological change in the cells toward a significant increase in the adhesion of cultured HPMCs
fibroblastic phenotype. HB-EGF is also broadly mito- to purified collagen type I (Fig. 6A). The basal adhesion
genic and binds to the same class of receptors as EGF, to collagen, as well as that induced by HB-EGF, was
so we were not surprised to find that it also induced both effectively inhibited by a monoclonal antibody that
binds to b1 integrins (P5D2). HB-EGF also increasedthe same morphological change and increased HPMC
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Fig. 3. mRNA for human EGF receptors (HER) -1 and -4 (HB-EGF
receptors) and HER-2 and -3 is detectable in peritoneal biopsies and
cultured HPMC from CAPD patients. Biopsies and cells were obtained
and RT-PCR was performed as described in the Methods section. The
lanes and expected product sizes are as follows: lane 1, GAPDH (417
bp); lane 2, HER-1 (493 bp); lane 3, HER-2 (692 bp); lane 4, HER-3 (219
bp); and lane 5, HER-4 (519 bp). The data shown are a representative
example of results obtained from four separate patients.
the expression of b1 integrins by HPMCs, as detected
by the same monoclonal antibody using flow cytometric
analysis (Fig. 6B).
Another key component of mesothelial wound healing
that may be modified by HB-EGF is directed cell migra-
tion. We tested the effect of HB-EGF on HPMC migra-
Fig. 4. Cell surface molecules associated with HB-EGF [CD9, CD49ction using two in vitro systems (Methods section). The (integrin a3 chain), and CD44] are expressed by cultured HPMCs from
first was a wound-healing assay in which a monolayer of CAPD patients. Flow cytometric analysis of HPMCs stained with spe-
cific monoclonal antibodies was performed as described in the Methodscells, grown on collagen type I, was scrape wounded,
section (–ve, irrelevant monoclonal antibody control). An illustrativeand the directed repair of the monolayer measured over result is taken from experiments performed on cells isolated from four
hours to days. HPMCs, grown on purified collagen type different patients.
I, migrated more rapidly to cover the wounded mono-
layer in the presence of HB-EGF (10 ng/mL; Fig. 7A).
The second assay used a modified Boyden chamber in
and ultrafiltration functions. Wound healing in other set-which a suspension of cells was placed in a chamber
tings is regulated by growth factors, including membersseparated from a chemoattractant (collagen type I) by
of the EGF family, and we hypothesized that they alsoa semiporous membrane. The appearance of cells in the
have an important role in maintaining peritoneal mem-opposite chamber was measured after several hours, pro-
brane integrity in CAPD patients. This article concen-viding a quantitative measure of their movement across
trated on HB-EGF, which is a heparin-binding memberthe membrane barrier. The short duration (4 h) of this
of the EGF family that is a potent mitogen and chemotac-assay effectively precluded a significant contribution from
tic factor for fibroblasts, keratinocytes, and smooth mus-growth factor-induced proliferation of the HPMCs. The
cle cells, but not endothelial cells [32].same concentration of HB-EGF induced a similar en-
Heparin-binding EGF-like growth factor is synthe-hancement of migration in this chemotaxis assay (Fig. 7B).
sized by a wide variety of tissues, and an important source
is activated macrophages. Soluble mature HB-EGF is pro-
DISCUSSION teolytically processed from a larger membrane-anchored
precursor, which also happens to be the receptor forEfficient and ordered healing of the damaged perito-
neal membrane is desirable in order to preserve dialysis diphtheria toxin [33]. It is closely associated on the cell
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Fig. 5. HB-EGF and its receptors HER-1 and -4 colocalize in HPMCs. (A and D) Permeabilized HPMC stained with the monoclonal antibody
DE10 against HB-EGF (green) and counterstained for DNA (blue). (B and E) Stained for HER-1 and HER-4, respectively (red), and DNA
counterstained (blue). (C and F) Colocalization of HB-EGF (green) with HER-1 and -4, respectively (red), counterstained for DNA (blue). Areas
of colocalization of HB-EGF with its receptor result in a cumulation of the emission, which appears yellow.
surface with integrin a3b1 [34], the tetraspanin CD9 cifically recognized by the DE10 monoclonal antibody)
on the surface of peritoneal macrophages and cultured[35–37], and the adhesion molecule CD44 [38], as well
as heparan sulfate proteoglycans. An association with HPMCs. mRNA for the receptors for HB-EGF (HER-1
and -4) is also detectable in peritoneal biopsies and cul-these adhesion molecules may be required for some of
the biological activities of HB-EGF. HB-EGF is recog- tured HPMCs, and molecules normally associated with
HB-EGF on the cell surface (a3b1, CD9, CD44) are allnized by two of the known EGF family receptors (HER-1
and HER-4). Binding to HER-1 induces proliferation, expressed by HPMCs. HB-EGF highly colocalizes with
both HER-1 and HER-4 in the HPMCs, which supportswhile binding to HER-4 induces chemotaxis [39]. HB-
EGF has been implicated in a variety of normal and the hypothesis that HB-EGF has functionally significant
effects on these cells. The in vitro studies with culturedpathological processes, including wound healing [8, 32],
and has been identified in wound fluid following injury HPMCs show that exogenous HB-EGF induces prolifer-
ation, transformation into a more fibroblastoid pheno-[40], where an important source is the infiltrating macro-
phages. HB-EGF production is induced in cultured hu- type, b1 integrin-dependent adhesion to collagen type I,
migration over and toward collagen type I (in bothman aortic endothelial cells following exposure to high
glucose and hyperosmolarity [41]. wound healing and chemotaxis assays), and increased
expression of b1 integrins. The latter effect of HB-EGFThe experiments summarized in this article show that
HB-EGF is expressed in the peritoneal cavity of CAPD has also been observed in cultured renal epithelial cells
[42] and human breast cancer cells [43]. These effects ofpatients and that it modifies a number of mesothelial
cell functions. mRNA for HB-EGF is detectable in peri- HB-EGF on HPMCs are consistent with its effects on
other cells and suggest that it will facilitate the mesothe-toneal leukocytes, peritoneal membrane biopsies, and
cultured HPMCs. Flow cytometric analysis confirms ex- lial cell response to wounding of the monolayer lining
the peritoneal membrane. A similar model of woundpression of the mature, soluble form of HB-EGF (spe-
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Fig. 6. HB-EGF (10 ng/mL for 4 days; A) induces a significant (P ,
0.01, two-tailed t-test) increase in the adhesion of HPMC to collagen
type I, and both the basal and stimulated adhesion are inhibited by a
monoclonal antibody against b1 integrins, and (B) the same treatment
induces a significant (P , 0.01, ANOVA) increase in their expression
of b1 integrins. Adhesion of HPMC to collagen type I, in the presence
or absence of the blocking anti-b1 monoclonal antibody P5D2, and
flow cytometric analysis of cell surface b1 integrins using P5D2 were
as described in the Methods section. Similar results were obtained in
separate experiments with cells obtained from three different patients.
Symbols are: ( ) no HB-EGF; ( ) 1 HB-EGF.
healing with peritoneal mesothelial cells was developed
independently by Yung and Davies [44], and their find-
ings are relevant to our studies. They found that meso-
thelial cells at the wound edge rapidly organized intracel-
lular actin stress fibers associated with focal adhesions, Fig. 7. HB-EGF (10 ng/mL for 4 days; A) increases the migration of
HPMC over collagen type I in a wound healing assay and (B) increasestransforming the cells to a migratory phenotype not dis-
their migration toward collagen type I in a chemotaxis assay. EGF (10similar to that induced by HB-EGF or EGF [4]. Wound
ng/mL) also stimulated chemotaxis of the HPMCs, but TNF-a (0.2
repair in the Yung model was dependent on cell migra- ng/mL) had no effect. Isolation and culture of HPMC and the wound
healing and chemotaxis assays were performed as described in thetion rather than cell proliferation and was more rapid
Methods section. Similar results were obtained in separate experimentsin the presence of FCS. We included FCS in our wound-
with cells obtained from three different patients. Symbols in A are:
healing experiments to facilitate cell viability for the ( ) HB-EGF; (s) untreated.
prolonged (days) duration of the assay and still found
that HB-EGF–treated cells migrated to cover the wound
more rapidly.
the peritoneal dialysate (particularly its hyperosmolarityGrowth factors such as HB-EGF are typically released
and hyperglycemia) is responsible for the persistence ofat the site of wounding by activated macrophages and
HB-EGF. The sustained expression of this and otherby the wounded cells (for example, keratinocytes) [8].
fibrogenic growth factors (such as TGF-b) may accountThe data reported in this article show that HB-EGF
for the observed association between duration of perito-is expressed under basal, noninfected conditions in the
neal dialysis (particularly with high glucose-containingperitoneal cavity of CAPD patients. Peritoneal macro-
dialysate) and peritoneal membrane fibrosis. Episodesphages from these patients usually exhibit an activated
of peritonitis, and the associated acute inflammation,phenotype [10, 11], and peritoneal dialysate is a recog-
may stimulate further release of HB-EGF and othernized irritant to peritoneal mesothelial cells [1–3], which
growth factors and hence exacerbate the fibrotic process.could explain the persistent expression. This situation
may be deleterious, as HB-EGF is also mitogenic and
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